Compare MTH & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTH | LQDA |
|---|---|---|
| Founded | 1985 | 2004 |
| Country | United States | United States |
| Employees | N/A | 216 |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.9B |
| IPO Year | 1997 | 2020 |
| Metric | MTH | LQDA |
|---|---|---|
| Price | $61.76 | $54.43 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 8 |
| Target Price | ★ $69.63 | $66.13 |
| AVG Volume (30 Days) | 911.4K | ★ 2.4M |
| Earning Date | 10-28-2026 | 11-10-2026 |
| Dividend Yield | ★ 3.13% | N/A |
| EPS Growth | N/A | ★ 51.81 |
| EPS | ★ 3.22 | N/A |
| Revenue | N/A | ★ $158,320,000.00 |
| Revenue This Year | N/A | $379.76 |
| Revenue Next Year | $2.85 | $25.58 |
| P/E Ratio | $19.04 | ★ N/A |
| Revenue Growth | N/A | ★ 1031.18 |
| 52 Week Low | $56.66 | $22.31 |
| 52 Week High | $85.38 | $93.61 |
| Indicator | MTH | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 43.50 | 58.91 |
| Support Level | $57.94 | $53.06 |
| Resistance Level | $76.89 | $59.50 |
| Average True Range (ATR) | 2.29 | 3.44 |
| MACD | -0.79 | 1.01 |
| Stochastic Oscillator | 8.85 | 71.72 |
Meritage Homes Corp is engaged as a designer and builder of single-family attached and detached homes. It has operations in three regions: West, Central, and East, comprising twelve states: Arizona, California, Colorado, Utah, Tennessee, Texas, Alabama, Florida, Georgia, Mississippi, North Carolina, and South Carolina. The company operates with two principal business segments: homebuilding and financial services. The homebuilding segments are engaged in the business of acquiring and developing land, constructing homes, marketing and selling those homes, and providing warranty and customer services, and the financial services segment offers title and escrow, mortgage, and insurance services. The company generates key revenue from the Homebuilding segment.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.